NS5B site 1 inhibitor - Bristol-Myers Squibb
Latest Information Update: 12 Nov 2013
At a glance
- Originator Bristol-Myers Squibb
- Mechanism of Action Hepatitis C virus NS 5 protein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Hepatitis C
Most Recent Events
- 07 Nov 2013 Discontinued for Hepatitis C in USA (unspecified route)
- 31 Dec 2011 Investigation in Hepatitis C in USA (unspecified route)